UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript March 2, 2026
UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.53552, expectations were $-0.66.
Operator: Good day, and thank you for standing by. Welcome to UroGen Pharma Ltd.’s fourth quarter 2025 earnings call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press...
